CLS_B: Revenue quadrupled and losses narrowed as neurosurgery focus and US expansion accelerated

About this update from Clinical Laserthermia Systems Ab Class B

Net sales grew 400% year-over-year in H1 2024, driven by neurosurgery segment focus and US market expansion. Losses narrowed, equity ratio improved, and a SEK 38 million rights issue was completed.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Clinical Laserthermia Systems Ab Class B